Your browser doesn't support javascript.
loading
Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages.
Arlauckas, Sean P; Garren, Seth B; Garris, Chris S; Kohler, Rainer H; Oh, Juhyun; Pittet, Mikael J; Weissleder, Ralph.
Affiliation
  • Arlauckas SP; Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA 02114.
  • Garren SB; Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA 02114.
  • Garris CS; Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA 02114.
  • Kohler RH; Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA 02114.
  • Oh J; Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA 02114.
  • Pittet MJ; Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA 02114.
  • Weissleder R; Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA 02114.
Theranostics ; 8(21): 5842-5854, 2018.
Article in En | MEDLINE | ID: mdl-30613266
ABSTRACT
Tumor-associated macrophages (TAM) have attracted attention as they can modulate key cancer-related activities, yet TAM represent a heterogenous group of cells that remain incompletely characterized. In growing tumors, TAM are often referred to as M2-like macrophages, which are cells that display immunosuppressive and tumorigenic functions and express the enzyme arginase 1 (Arg1).

Methods:

Here we combined high resolution intravital imaging with single cell RNA seq to uncover the topography and molecular profiles of immunosuppressive macrophages in mice. We further assessed how immunotherapeutic interventions impact these cells directly in vivo.

Results:

We show that i) Arg1+ macrophages are more abundant in tumors compared to other organs; ii) there exist two morphologically distinct subsets of Arg1 TAM defined by previously unknown markers (Gbp2b, Bst1, Sgk1, Pmepa1, Ms4a7); iii) anti-Programmed Cell Death-1 (aPD-1) therapy decreases the number of Arg1+ TAM while increasing Arg1- TAM; iv) accordingly, pharmacological inhibition of arginase 1 does not synergize with aPD-1 therapy.

Conclusion:

Overall, this research shows how powerful complementary single cell analytical approaches can be used to improve our understanding of drug action in vivo.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Arginase / Gene Expression / Immune Tolerance / Lymphoma / Macrophages / Melanoma Type of study: Risk_factors_studies Language: En Journal: Theranostics Year: 2018 Type: Article

Full text: 1 Database: MEDLINE Main subject: Arginase / Gene Expression / Immune Tolerance / Lymphoma / Macrophages / Melanoma Type of study: Risk_factors_studies Language: En Journal: Theranostics Year: 2018 Type: Article